Stem cell therapies, regenerative medicine, tissue engineering, and cellular reprogramming
170 articles
A phase 2b trial finds allogeneic MSC infusions improved 6-minute walk distance by 63 meters vs placebo at 9 months in frail older adults.
Cytosine base editing achieved 62–89% efficiency fixing a hyperinflammatory disease gene, but revealed distinct genotoxicity risks across cell types.
A special issue overview surveys three decades of peptide-based materials research, spotlighting applications from drug delivery to regenerative medicine.
A landmark clinical trial transplanted iPSC-derived dopamine neurons into Parkinson's patients using only tacrolimus — with no significant immune rejection.
Researchers 3D-printed silicone scaffolds seeded with human iPSC-derived spinal neural progenitor cells, transplanted them into transected rat spinal cords, and observed significant functional recovery at 12 weeks.
Master the cutting-edge science of exosome engineering, delivery pharmacokinetics, and clinical translation — from CRISPR-loaded nanoparticles to the molecular logic of next-generation regenerative therapies.
A Phase 1/2 trial tests four rounds of intrathecal MSC injections in ALS patients, targeting both safety and disease progression.
New research in Nature Aging suggests tissue mechanical softness is a critical factor enabling cellular regeneration, with major implications for aging biology.
Go deeper into how exosomes are built, what they carry, and how their molecular cargo rewires receiving cells — with implications for regeneration, aging, and emerging therapies.
Harvard's CellCartographer uses machine learning to identify optimal transcription factor combinations for rapid, high-efficiency cell reprogramming.
Kyoto researchers created jawbone-like organoids from human iPSCs, recapitulating mandibular development and modeling fragile bone disease.
Chinese researchers decode how chemical cocktails alone can convert adult human cells into pluripotent stem cells, bypassing gene editing.
